Sg Americas Securities, LLC Prothena Corp Public LTD CO Transaction History

Sg Americas Securities, LLC

  • $24.4 Billion
  • Q4 2024

A detailed history of Sg Americas Securities, LLC transactions in Prothena Corp Public LTD CO stock. As of the latest transaction made, Sg Americas Securities, LLC holds 37,612 shares of PRTA stock, worth $530,705. This represents 0.0% of its overall portfolio holdings.

Number of Shares
37,612
Previous 14,087 167.0%
Holding current value
$530,705
Previous $236,000 120.76%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 17, 2025
BUY
$11.95 - $18.35 $281,123 - $431,683
23,525 Added 167.0%
37,612 $521,000
Q3 2024

Oct 03, 2024
SELL
$16.73 - $24.79 $677,314 - $1 Million
-40,485 Reduced 74.19%
14,087 $236,000
Q2 2024

Jul 12, 2024
BUY
$19.54 - $26.15 $739,628 - $989,829
37,852 Added 226.39%
54,572 $1.13 Million
Q1 2024

May 06, 2024
SELL
$24.75 - $40.66 $2.95 Million - $4.84 Million
-119,137 Reduced 87.69%
16,720 $414,000
Q4 2023

Jan 12, 2024
BUY
$32.31 - $52.32 $1.4 Million - $2.27 Million
43,363 Added 46.88%
135,857 $4.94 Million
Q3 2023

Oct 13, 2023
BUY
$47.3 - $70.6 $4.21 Million - $6.28 Million
88,939 Added 2501.8%
92,494 $4.46 Million
Q2 2023

Jul 10, 2023
SELL
$48.26 - $78.59 $5.11 Million - $8.32 Million
-105,846 Reduced 96.75%
3,555 $243,000
Q1 2023

Apr 28, 2023
BUY
$46.97 - $58.27 $1.44 Million - $1.78 Million
30,629 Added 38.88%
109,401 $5.3 Million
Q4 2022

Feb 02, 2023
SELL
$52.05 - $65.0 $2.96 Million - $3.69 Million
-56,816 Reduced 41.9%
78,772 $4.75 Million
Q3 2022

Oct 31, 2022
SELL
$25.16 - $60.63 $478,040 - $1.15 Million
-19,000 Reduced 12.29%
135,588 $8.22 Million
Q2 2022

Jul 29, 2022
BUY
$22.73 - $39.98 $251,893 - $443,058
11,082 Added 7.72%
154,588 $4.2 Million
Q1 2022

Apr 29, 2022
SELL
$30.27 - $49.22 $343,170 - $558,007
-11,337 Reduced 7.32%
143,506 $5.25 Million
Q4 2021

Feb 07, 2022
BUY
$42.11 - $73.26 $1.63 Million - $2.84 Million
38,767 Added 33.4%
154,843 $7.65 Million
Q3 2021

Nov 01, 2021
BUY
$48.2 - $78.89 $5.11 Million - $8.37 Million
106,056 Added 1058.44%
116,076 $8.27 Million
Q2 2021

Aug 12, 2021
SELL
$21.63 - $57.65 $11,247 - $29,978
-520 Reduced 4.93%
10,020 $515,000
Q1 2021

May 13, 2021
SELL
$11.0 - $28.24 $31,229 - $80,173
-2,839 Reduced 21.22%
10,540 $265,000
Q4 2020

Feb 04, 2021
BUY
$10.12 - $13.94 $135,395 - $186,503
13,379 New
13,379 $161,000
Q3 2020

Nov 09, 2020
SELL
$9.93 - $13.47 $120,927 - $164,037
-12,178 Closed
0 $0
Q2 2020

Jul 20, 2020
SELL
$9.56 - $12.51 $41,633 - $54,481
-4,355 Reduced 26.34%
12,178 $127,000
Q1 2020

Apr 30, 2020
BUY
$7.54 - $15.77 $55,788 - $116,682
7,399 Added 81.01%
16,533 $177,000
Q4 2019

Jan 28, 2020
BUY
$7.48 - $17.01 $68,322 - $155,369
9,134 New
9,134 $145,000
Q2 2019

Jul 29, 2019
SELL
$8.85 - $12.49 $82,871 - $116,956
-9,364 Closed
0 $0
Q1 2019

Apr 29, 2019
BUY
$10.32 - $14.49 $96,636 - $135,684
9,364 New
9,364 $114,000
Q3 2018

Nov 06, 2018
SELL
$12.7 - $15.79 $89,027 - $110,687
-7,010 Closed
0 $0
Q2 2018

Aug 07, 2018
BUY
$10.99 - $44.21 $10,891 - $43,812
991 Added 16.46%
7,010 $102,000
Q1 2018

May 03, 2018
BUY
$27.95 - $45.04 $36,670 - $59,092
1,312 Added 27.87%
6,019 $221,000
Q4 2017

Jan 24, 2018
SELL
$35.44 - $63.76 $79,208 - $142,503
-2,235 Reduced 32.2%
4,707 $176,000
Q3 2017

Nov 07, 2017
BUY
$53.83 - $67.75 $373,687 - $470,320
6,942
6,942 $450,000

Others Institutions Holding PRTA

# of Institutions
186
Shares Held
42.8M
Call Options Held
162K
Put Options Held
102K
View Full List

About PROTHENA CORP PUBLIC LTD CO

PRTA Quotes by TradingView
  • Ticker PRTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,922,800
  • Market Cap $662M
  • Description
  • Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...
More about PRTA
Track This Portfolio

Track Sg Americas Securities, LLC Portfolio

Follow Sg Americas Securities, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sg Americas Securities, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sg Americas Securities, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email